Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded to Outperfo

SVB Leerink upgraded shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) from a market perform rating to an outperform rating in a report published on Wednesday morning, PriceTargets.com reports. SVB Leerink also issued estimates for Arrowhead Pharmaceuticals’ Q2 2023 earnings at ($0.02) EPS, Q3 2023 earnings at ($0.02) EPS, Q4 2023 earnings at $0.33 EPS, […]

Related Keywords

, Piper Sandler , Adeoyey Olukotun , News Ratings For Arrowhead Pharmaceuticals Daily , Arrowhead Pharmaceuticals , Arrowhead Pharmaceuticals Company Profile , Analyst Recommendations For Arrowhead Pharmaceuticals , Securities Exchange Commission , Raymond James Associates , Arrowhead Pharmaceuticals Stock Down , Nasdaq , Exchange Traded Concepts , Stonnington Group , Insider Activity At Arrowhead Pharmaceuticals , Arrowhead Pharmaceuticals Inc , Allspring Global Investments Holdings , Get Rating , Moderate Buy , Pharmaceuticals Stock Down , Director Adeoye , Exchange Commission , Director Douglas , Global Investments Holdings , Traded Concepts , Arrowhead Pharmaceuticals Daily , Nasdaq Arwr , Arwr , Medical , Upgrade , Svb Leerink Llc ,